Both Pain, Depression Reduced by Inhibiting TRPV1 in Fibromyalgia Mouse Model, Study Shows

Both Pain, Depression Reduced by Inhibiting TRPV1 in Fibromyalgia Mouse Model, Study Shows
Inhibiting the nerve cell receptor TRPV1 led to the dual effect of reducing both pain perception and depressive-like behaviors in a mouse model of fibromyalgia, a preliminary study showed. The study, “Involvement of TRPV1 and the efficacy of α-spinasterol on experimental fibromyalgia symptoms in mice,” was published in the journal Neurochemistry International.  Fibromyalgia is characterized by widespread chronic pain. A large proportion of patients also deal with debilitating comorbidities — having two chronic diseases or conditions at the same time — such as moderate-to-severe depression and anxiety. Conversely, people with depression report an increased perception of pain and are more likely to develop chronic pain, the researchers said.  As these conditions often occur together, "it is highly relevant to identify a compound with a dual-action that could treat both pain and depression symptoms," the investigators said.   A protein receptor on the surface of cells in the nervous system — named the transient receptor potential vanilloid 1 (TRPV1) — was previously found to be implicated in the development of pain sensitivity and depressive-like behaviors.  Moreover, blocking this receptor in mice, or removing it altogether, led to anti-depressive behavior, while TRPV1 inhibition reduced pain perception in preclinical and clinical studies.  Despite studies showing that TRPV1 activation is associated with increased pain perception in a fibromyalgia mouse model, the effects of targeting TRPV1 with a single therapy able to treat both pain and depression has not been evaluated.  Thus, a team of investigators based at the Federal University of Santa Maria, in Brazil, tested the known TRPV1 inhibitors α-spinasterol — a chemical foun
Subscribe or to access all post and page content.